01—Abstract
Summary
Summary of the 8-K filed January 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. has filed an 8-K report on January 5, 2026, primarily disclosing a letter sent to its shareholders.
This letter, attached as Exhibit 99.1, is intended to provide an update and is being furnished under Regulation FD, meaning it's not considered 'filed' for liability purposes under Section 18 of the Exchange Act. While the specific content of the shareholder letter is not detailed in the 8-K itself, its issuance suggests the company is proactively communicating significant information to its investors. Investors should look to the attached Exhibit 99.1 for the core details of Moderna's communication.
Given the typical nature of such letters, it is likely to cover key business developments, strategic updates, or financial performance commentary. The filing serves as an official record of this communication, ensuring transparency and broad dissemination of information to all shareholders.
02—Key points
Key Highlights
- Moderna, Inc. issued a shareholder letter on January 5, 2026.
- The shareholder letter is filed as Exhibit 99.1 to the 8-K.
- The disclosure is made under Regulation FD to ensure broad and non-exclusionary communication.
- The information furnished is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing does not provide specific details of the letter's content but includes it as an exhibit.
- Investors are directed to Exhibit 99.1 for the full content of the shareholder communication.
- An interactive data file (Cover Page) is also included as Exhibit 104.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to publicly disclose a letter that Moderna, Inc. sent to its shareholders on January 5, 2026. This ensures that the information communicated in the letter is available to all investors simultaneously.
Where can I find the details of what Moderna communicated to its shareholders?
The detailed content of the shareholder letter is provided as Exhibit 99.1 to this 8-K filing. You will need to review Exhibit 99.1 for the specific information and updates Moderna shared.
Is the information in this filing legally considered 'filed' by Moderna?
No, the information furnished under Item 7.01, including the shareholder letter, is intended to be furnished and is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This generally means it does not carry the same legal liabilities as information formally filed with the SEC.
What are the implications of this filing for investors?
For investors, this filing signifies that Moderna is providing an update or sharing significant news directly with its shareholders. The key is to examine the content of Exhibit 99.1 to understand the company's current status, outlook, or any material developments they are announcing.
04—Continue